Day: September 1, 2021

$AGGL – Galexxy Holdings Inc. Announces its Genus CBD BrandGenus CBD BrandNewport Beach, California, Sept. 01, 2021 (GLOBE NEWSWIRE) — Galexxy Holdings Inc. (formerly Agtech) [OTC Pink: AGGL] is pleased to announce that its Genus™ CBD product brand soon to be launched by Galexxy Corporation, has been successfully trademarked. The term “Genus” is borrowed from Latin, and it is a biological classification, ranking between a plant family and species. As a wholly-owned subsidiary, Galexxy Corporation will market Genus™ CBD products online direct to consumers, using its patent pending Virtual Retail Marketing System™ (VRMS). VRMS is a unique hybrid retailing approach combining the physical attributes of the “Brick & Mortar” customer experience with the ease and convenience of online digital shopping. The...

Move will Support Thousands of Affordable Multifamily Housing Units in Nation’s Most Underserved Communities MCLEAN, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) will begin ramping up its Low-Income Housing Tax Credit (LIHTC) equity investments, which support affordable housing throughout the United States. The move comes in response to the Federal Housing Finance Agency’s (FHFA) announcement that it has increased the annual cap on Freddie Mac’s LIHTC Equity investments from $500 million to $850 million. Freddie Mac has provided approximately $500 million in LIHTC Equity investments each year since reentering the market in 2018. “Freddie Mac has built a robust LIHTC Equity investment program, with more than 120 investments in 26 states and Puerto Rico and Guam since 2018,” said Debby Jenkins, executive vice...

SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for toripalimab in combination with gemcitabine and cisplatin for first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and toripalimab monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA recently granted Breakthrough Therapy Designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for 1st line treatment...

GENEVA, Sept. 01, 2021 (GLOBE NEWSWIRE) — Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX) announces that further to the recent sale of substantially all of the Company’s assets and the return of capital to shareholders that was completed on August 24, 2021, and in order to minimize the costs and management time associated with the listing of the Corporation’s common shares (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”) and Nasdaq Stockholm (“Nasdaq”) pending a determination of whether the Company should pursue an alternative business or an orderly dissolution and winding-up of the Company, the Company has applied to voluntarily delist the Common Shares from the TSX. Such delisting will become effective after the close of trading on September 17, 2021. The Company also intends to apply to delist...

Press release Bergman & Beving acquires 3 Screen Workplace Safety, a division within Bergman & Beving, has today acquired all shares in (3) Screen Tryck AB. 3 Screen will become part of the business area Safety & Industrial Signage (SIS Group), together with the companies Systemtext and JO Safety. 3 Screen is a niche producer of workplace safety signage products. The acquisition brings unique production capabilities of patented products. The company has an annual turnover of approximately MSEK 7 with strong profitability and is based in Malmö with five employees. “With the acquisition of 3 Screen, we continue to invest in the niche market of workplace safety signage”, says Fredrik Valentin, Head of Division Workplace Safety. “We intend to further develop the company as an integrated part of SIS Group, gaining competitive...

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. Event: H.C. Wainwright 23rd Annual Global Investment ConferenceMonday, September 13 – Wednesday, September 15 A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am EDT, Monday, September 13. It can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About...